Aug 21, 2019
The U.S. Food and Drug Administration has approved WAKIX (pitolisant) to treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy. The Narcolepsy therapy, developed by HARMONY therapeutics, is the first and the only treatment to get approval that is not labelled as a controlled substance by the US...
Read More...
Apr 03, 2017
Narcolepsy is characterized by symptoms such as excessive daytime sleepiness, cataplexy (sudden loss of muscle control, often triggered by strong emotions) and fragmented sleep. Narcolepsy occurs throughout the world but occurrence rates vary among populations. Occurrence of Narcolepsy is estimated to be 1 in 2,000 ...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper